174 related articles for article (PubMed ID: 25588152)
1. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
JAMA Dermatol; 2015 Apr; 151(4):410-6. PubMed ID: 25588152
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
3. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
Manfredi L; Meyer N; Tournier E; Grand D; Uro-Coste E; Rochaix P; Brousset P; Lamant L
Acta Derm Venereol; 2016 Jun; 96(5):630-4. PubMed ID: 26695089
[TBL] [Abstract][Full Text] [Related]
4. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
6. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
7. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
8. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
9. Intrapatient homogeneity of BRAFV600E expression in melanoma.
Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
[TBL] [Abstract][Full Text] [Related]
10. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
12. Intra- and Inter-Tumor
Ito T; Kaku-Ito Y; Murata M; Ichiki T; Kuma Y; Tanaka Y; Ide T; Ohno F; Wada-Ohno M; Yamada Y; Oda Y; Furue M
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817947
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
14. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).
Long E; Ilie M; Lassalle S; Butori C; Poissonnet G; Washetine K; Mouroux J; Lespinet V; Lacour JP; Taly V; Laurent-Puig P; Bahadoran P; Hofman V; Hofman P
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2436-43. PubMed ID: 26377147
[TBL] [Abstract][Full Text] [Related]
15. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
16. The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability.
Nolan S; Arnason T; Drucker A; Huang WY
Appl Immunohistochem Mol Morphol; 2014; 22(5):e8-e13. PubMed ID: 24805134
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
18. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
[No Abstract] [Full Text] [Related]
19. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]